Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHP Enbrel Market Expansion Plans Include Up To 2.4 Mil. U.S. Patients

Executive Summary

The next step in Wyeth-Ayerst's plans to expand the market for Enbrel will be the presentation of the pivotal trial data in early rheumatoid arthritis during the upcoming American College of Rheumatology conference in Boston, Nov. 13-17.

You may also be interested in...



Wyeth Prevenar Approval Expected By End of February

Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.

Wyeth Prevenar Approval Expected By End of February

Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.

Immunex Novantrone MS Use Is Likely To Be Second-Line

Immunex expects Novantrone (mitoxantrone) would be used primarily as second-line therapy if approved for the treatment of multiple sclerosis.

Related Content

UsernamePublicRestriction

Register

PS035028

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel